Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synergy Outsourcing partners with ChemOvation
Synergy Outsourcing, part of UK based scientific recruiter SRG, is a functional service provider of on and off site outsourced services across the chemistry, quality and biochemistry industries.
Synergy Outsourcing, part of UK based scientific recruiter SRG, is a functional service provider of on and off site outsourced services across the chemistry, quality and biochemistry industries.
MetMAb, a monovalent (one-armed), monoclonal antibody is designed to block Met signaling in cancer cells by binding specifically to the cell surface Met receptor, blocking HGF-mediated activation. MetMAb
TissueGene expects to recruit around 100 patients in the trial across US. In the Phase II trial, the patients will be given intra-articular injection of either TG-C or
Imprime PGG is a novel immunomodulatory drug in development as a cancer therapy. The company expects to recruit around 795 patients in over 50 locations worldwide, including the
Dexamethasone elixir, a corticosteroid, is indicated for the treatment for variety of conditions including endocrine disorders, rheumatic disorders, and collagen diseases. Dexamethasone elixir works by decreasing or preventing
The acquisition will allow Takeda to add roflumilast franchise (Daxas; trade name in Europe), indicated as the treatment for chronic obstructive pulmonary disease (COPD), into its product portfolio
Levocetirizine Solution, 2.5 mg/5ml is the generic version of UCB’s Xyzal Oral Solution, indicated for the treatment of indoor and outdoor allergies. Synthon and UCB are currently engaged
CATS1 Phase I/II trial intends to investigate the tolerability and efficacy of Ovasave, a type 1 regulatory T cell based immunotherapy, in patients with severe chronic active Crohn’s
Medical Office Online is a 2011-2012 ONC-ATCB certified integrated solution which meets the requirements for meaningful use and is therefore eligible for funding through the federal government’s ARRA
Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, receptors that can influence tumor growth, vascular angiogenesis and progression